1. The FBI would DEFINITELY have a copy of your record of criminal
conviction in CT;

2. The fact that you're not "of investigative interest" to the FBI is
something you consider an accomplishment? It doesn't say that you don't
have a FBI file.

3. Why would you post "Hey!  How come I don't have such a dossier!!
FBI told me I don't have such a file, which I consider to be an insult
to my true patriotism.  People who haven't been identified as an enemy
of the Bush Administration, can't be true patriots.  I WANT A
DOSSIER!!!  INVESTIGATE ME!!!"

4. The fact that the FBI hasn't investigated you for your clear threats
of terrorism indicates the same kind of sloth and incompetence that led
to 9/11--as in the 9/11 example, they HAD the information and did
nothing about it. All the absence of this dossier indicates is that the
FBI remains incompetent;

5. You are a MONSTER MOM a FELON a LIAR a FRAUD a POSER a FAKE a
TERRORIST a HOLOCAUST DENYING ANTI SEMITIC PIECE OF sh.t

6. Since you ask I will NOW report you to the FBI as per below--I will
provide them with the post where you advise that people try to crash
the FBI computers (See below):

Have fun!

What right do you have to mercilessly defame the names of good public
serveants like richard
blumenthal, kevin O'connor, Jessica Gauvin, Judge Clifford etc.

You're a LOSER

Who's the loser kathLOON? Who's life consists of posting 24/7/365
instead of having a family, taking care of your children, getting
yourself the mental help you so DESPERATELY need?

Who has no job, no family, no prospects, no friends? And a record of
felony conviction and institutionalization?

YOU!

Look in the mirror to see the LOSER!
Such as KATHLEEN DICKSON!!!

You've been blathering the same thing for YEARS and the scorecard still

reads:

kathLOON: charged, convicted, sentenced, no appeal FELON

Kathloon's proclaimed enemies: all free and clear

(no governor rowland doesn't count since you had NOTHING to do with
it!)

And your bizarre and delusional OBSESSIONS about mcsweegan are as
baseless as your soon to be dismissed lawsuits.

Get some help kathLOON.

Come on kathLOON. It is TIME to FINALLY answer the questions.

Tell us WHAT is NOT TRUE about you:
You were accused tried and convicted did not appeal and never have had
anyone but you declare yourself innocent or the charges false.

Shut up already. And answer the questions below.

You're a DELIBERATE LIAR!

KATHLEEN IT AIN'T FUNNY STOP THE LIES YOU LYING LIAR!

Featured in Court & Police

Kathleen Dickson
Published on 5/8/2004

Kathleen Dickson, 46, of 23 Garden St., Pawcatuck, was charged Thursday

with being a fugitive from justice.

© The Day Publishing Co., 2004

Featured in Court & Police

Kathleen Dickson

Published on 5/9/2004

Kathleen Dickson, 45, of 23 Garden St., Pawcatuck, was charged Friday
with second-degree harassment and threatening.

© The Day Publishing Co., 2004

ANSWER THE QUESTIONS KATHLEEN

Let's see how you like it kathleen EVERY time you post, I will change
the title of the thread and I will post these questions until you
answer them one by one and answering them means NOT talking about
McSweegan or former Governor Rowland and all your typical diversionary
crap anyway.

PLUS you are cross posting ONCE AGAIN TOTALLY OFF TOPIC and you're
selfish to do this to one newsgroups CRIMINAL to do it to multiple
newsgroups--yes here is your "crime": You are preventing people who
need help from getting help for your selfish personal reasons that you
are so completely egocentric along with delusional paranoid
schizophrenic with psychotic features that you just can't see past your

own twisted delusional psychotic personal agenda--which ought to be
about getting your kids back and solving your own enormous problems in
life instead of trying to solve anyone else's. By preventing people
from getting help you are responsible for the consequences. Surely
people are dying as a result so you are a murderer (trying out a little

kathleen "logic" here. So you are now being reported to the DOJ FBI and

CIA and WHO and UN and DCF and the federal and state courts and
homeland insanity department and all over the planet as a murderer.

How do you like them apples?

Now answer the questions. And stop the off topic cross posting. Answer
the questions TRUTHFULLY for a change. Focus on the question. If
there's a question yOU don't understand which is hard to believe given
your self declared genius IQ, let us know and we'll rephrase it.

Don't LIE as you do and don't try your diversionary tactics. Ignore
this and I will keep reposting it kathleen. Not only that but your
silence will be construed as admissions to all OF the facts listed as
questions.

PS: This is NOT "taunting" You have put your credibility at issue. You
have repeatedly said that you NEVER lie. We deserve the answers to
these questions. Straight answers.

REPOST:

http://groups-beta.google.com/group/sci.med.diseases.lyme/browse_thre...

Nope we're talking about YOU. ANSWER THE QUESTIONS

And come back and tell us when Steere or McSweegan or anyone else is
actually charged with your "Lyme Crymes" instead of telling us what
you, in all your infinite wisdom, think will happen.

Now let's talk not about who WILL be convicted but WHO already has
been--YOU.

Here's the question list. One by one give us some answers. Your post is

just like the Bush White House trying to DIVERT attention from what
Karl Rove did to Joe Wilson--by attacking him AGAIN.

Nope answer the questions kathleen. Stop trying to change the subject.

I know you're delusional but try to focus. Here is a list of questions
for YOU. We've already heard your ramblings about 100,000 times. Now
dish some TRUTH for a change--I'm going to leave space between the
questions for your answers:

Was your case appealed and was your conviction overturned?

You CLAIM there is a court Order prohibiting you from criticizing the
government. Post it!

And what isn't true? Everything can be backed up with your own posts
kathleen. Not a big secret how people know since you posted it all
here.

Were you charged with and convicted of threatening and harassing
Jessica Gauvin?

Did you flee to Canada?

Did you tell everyone that your case was a custody case against DCF
when the truth was that it was a criminal case against you and your
kids had been taken away many months earlier and you didn't even appeal

that?

Did you threaten to bomb the stonington schools, joke or not?

Did you show up at your kid's safe house with a bag full of drugs
whether you meant to give them to your lawyer or not?

Come on specifically what isn't true?

You were charged tried and convicted in a court of law. Right or wrong,

admit or deny?

Now you say you've proven you're innocent.

In what court were your convictions overturned?

In fact, tell us what the charges were. Give some detail. What exactly
were you convicted of doing or threatening to do to Jessica Gauvin?

Tell us what your diagnosis was in the mental institution?

You admit or deny that your kids were taken away by child services in
CT?

Admit or deny you were charged with crimes?

Admit or deny you feld to canada?

Admit or deny you were convicted?

Admit or deny you were institutionalized in a mental ward locked wing?

Admit or deny that your convictions were never reversed, in fact you
never filed an appeal did you?

So who's lying about what?

Yeah sure, you say everyone lied about the charges. But that's not what

the court thought was it?

Did you register a website claiming on it you were working for Pfizer
at the time when you had "retired" years before?

Was Lymeraft which solicited funds for YOU, ever a proper legally
registered charity?

Kathleen you're the liar here.

Do you really expect everyone to believe that the rest of the world is
crazy, not you?

And that the rest if the world has conspired to frame you? Because of
your lyme activism which you have even admitted amounts to more posting

on the internet than any real accomplishments?
http://groups-beta.google.com/group/sci.med.diseases.lyme/browse_thre...

Come on kathleen. What isn't true specifically issue by issue above.

Tell us specifically which items you say aren't true. We can go back
and find the posts where you admitted stuff and show what a liar YOU
are!

And see kathleen's post advocating cyberterrorism:

http://groups-beta.google.com/group/sci.med.diseases.lyme/browse_thre...

This is a federal crime. A SERIOUS Federal Crime. So do what you think
is right! By the way this is almost certainly a violation of her
probation/parole.

Kathleen Dickson

860-599-5451
23 Garden St., Pawcatuck 06379

Remember, she's provided everyone with contact information for the FBI
in New Haven: FBI New Haven 203-777-6311

-------------------------------------------------------------------------------------------------------------------

kathLOON's post advocating cyber terrorism against the FBI:
http://groups.google.com/group/sci.med.diseases.lyme/msg/1390a1471d1d5561?&hl=en
&q=EWALD

kathleen
Jul 24, 11:48 am   hide options

Newsgroups: sci.med.diseases.lyme
From: "kathleen" <kathleen.dick...@snet.net> - Find messages by this
author
Date: 24 Jul 2005 09:48:37 -0700
Local: Sun, Jul 24 2005 11:48 am
Subject: Re: Countering "counterterrorism"
Reply to Author | Forward | Print | View Thread | Show original |
Report Abuse

1) Lyme is a borreliosis (a permanent brain infection), and we're not
"CRAZY"

Alan Barbour:
http://www.ucihs.uci.edu/microbio/index.html?top.html&menu.html&facul...

"These tick-borne infections are notable for multiphasic antigenic
variation through DNA recombinations in the case of relapsing fever,
the occurrence of chronic arthritis in the case of Lyme disease, and
invasion of and persistence in the brain in the case of both
diseases."

Borrelia and Brain (MedLine):  (nearly 200 citations)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&db=pubme...

2)  The blood testing standard for Lyme is bogus.  Steere knows there
is a different antibody profile for neuroborreliosis, and that OspA
(LymeRIX) and B produced strong antibodies in people with arthritis, so

it never should have been left out of the standard.

Borrelia is a "stealth pathogen," thus there is not typically a
high antibody response.

ALAN BARBOUR:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=P...

"Multiclonal populations therefore can exist in an infected patient
so that immunological defenses are severely tested if not totally
overwhelmed."

(1986) "Antigens of Borrelia" Allen Steere, in which he states that
antibodies to
borrelia include OspA and B, and that these bound strongly in persons
with Lyme arthritis.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

1: J Clin Invest. 1986 Oct;78(4):934-9.

Antigens of Borrelia burgdorferi recognized during Lyme disease.
Appearance of a
new immunoglobulin M response and expansion of the immunoglobulin G
response
late in the illness.

Craft JE, Fischer DK, Shimamoto GT, Steere AC.

Using immunoblots, we identified proteins of Borrelia burgdorferi bound

by IgM
and IgG antibodies during Lyme disease. In 12 patients with early
disease alone,
both the IgM and IgG responses were restricted primarily to a 41-kD
antigen.
This limited response disappeared within several months. In contrast,
among six
patients with prolonged illness, the IgM response to the 41-kD protein
sometimes
persisted for months to years, and late in the illness during
arthritis, a new
IgM response sometimes developed to a 34-kD component of the organism.
The IgG
response in these patients appeared in a characteristic sequential
pattern over
months to years to as many as 11 spirochetal antigens. The appearance
of a new
IgM response and the expansion of the IgG response late in the illness,

and the
lack of such responses in patients with early disease alone, suggest
that B.
burgdorferi remains alive throughout the illness.
PMID: 3531237 [PubMed - indexed for MEDLINE]

(1988)   "Changes in Infectivity and Plasmid Profile of the Lyme
Disease Spirochete..."   National Institute of Allergy and Infectious
Disease , (1988)
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

1: Infect Immun. 1988 Aug;56(8):1831-6.

Changes in infectivity and plasmid profile of the Lyme disease
spirochete,
Borrelia burgdorferi, as a result of in vitro cultivation.

Schwan TG, Burgdorfer W, Garon CF.

Laboratory of Pathobiology, Rocky Mountain Laboratories, National
Institue of
Allergy and Infectious Diseases, Hamilton, Montana 59840.

In vitro cultivation of Borrelia burgdorferi, the etiologic agent of
Lyme
spirochetosis, allows for the isolation and growth of this bacterium
from
infected tissues. However, continuous cultivation in modified Kelly
medium
causes a reduction in the number of detectable plasmids and the loss of

infectivity in the white-footed mouse, Peromyscus leucopus. In an
unpassaged
culture of B. burgdorferi, nine plasmids were present, including seven
linear
plasmids ranging in size from 49 to 16 kilobases (kb) and two circular
plasmids
of 27 and 7.6 kb. The 7.6-kb circular and 22-kb linear plasmids were no

longer
detectable in spirochetes noninfective in white-footed mice, suggesting

that a
gene(s) encoding for factors responsible for infection may be present
on one or
more of these extrachromosomal elements. Furthermore, changes in
spirochetal
proteins and lipopolysaccharide-like material were observed also during

early
cultivation and may be related to loss of infectivity.
PMID: 3397175 [PubMed - indexed for MEDLINE]

NIH:   Don't use high passage strains: They lose OspA and B plasmid
expression

(1988)  European Patent Application Number 93201345.1
Assigned to Alan Barbour, Louis Magnarelli, Sven Bergstrom

USA Patent #
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=P...

"It has been shown that the earliest IgM antibodies formed against
antigens of the B. burgdorferi strain B31, which was deposited in the
American Type Culture Collection in 1983 with the accession number ATCC

35210, are directed against a genus-specific flagellar poly-peptide
termed flagellin having a molecular weight of 41 kd (10) and which
reacts with monoclonal antibody H9724 (22). IgG antibodies are also
first directed to the 41 kd flagellin, but with advancing disease IgG
antibodies form against other immunogens, especially against two
abundant proteins with molecular weights of 31 kd and 34 kd. These two
proteins, which have been denoted OspA (31 kd) and OspB (34 kd), have
been found to be located at the B. burgdorferi surface and embedded in
its outer fluid cell membrane (11).

-OspA is meant to be a diagnostic antigen (it is now not)

1990     CDC Publication   Lyme blood testing standard:  Perform serial

Western blots

(1991)-  Yale, Fikrig, Borrelia specific flagellin fragment is 94.4%
accurate and does not cross react (is specific)
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

1: Infect Immun. 1991 Oct;59(10):3531-5.

Molecular characterization of the humoral response to the 41-kilodalton

flagellar antigen of Borrelia burgdorferi, the Lyme disease agent.

Berland R, Fikrig E, Rahn D, Hardin J, Flavell RA.

Section of Immunobiology, Yale University School of Medicine, New
Haven,
Connecticut 06510.

The earliest humoral response in patients infected with Borrelia
burgdorferi,
the agent of Lyme disease, is directed against the spirochete's 41-kDa
flagellar
antigen. In order to map the epitopes recognized on this antigen, 11
overlapping
fragments spanning the flagellin gene were cloned by polymerase chain
reaction
and inserted into an Escherichia coli expression vector which directed
their
expression as fusion proteins containing glutathione S-transferase at
the N
terminus and a flagellin fragment at the C terminus. Affinity-purified
fusion
proteins were assayed for reactivity on Western blots (immunoblots)
with sera
from patients with late-stage Lyme disease. The same immunodominant
domain was
bound by sera from 17 of 18 patients. This domain (comprising amino
acids 197 to
241) does not share significant homology with other bacterial
flagellins and
therefore may be useful in serological testing for Lyme disease.
PMID: 1894359 [PubMed - indexed for MEDLINE]

(1992) "Western blotting in the Serodiagnosis of Lyme Disease"
1992, July Dressler/Steere

Steere knowingly using a weakened strain intending to leave OspA and B
out of the serologic standard, decreasing the likelihood that people
will be diagnosed with Lyme disease, and with the intention of
capturing all the post-LymeRIX or ImmuLyme approval testing for Lyme.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

1: J Infect Dis. 1993 Feb;167(2):392-400.

Western blotting in the serodiagnosis of Lyme disease.

Dressler F, Whalen JA, Reinhardt BN, Steere AC.

Division of Rheumatology/Immunology, Tufts University School of
Medicine, New
England Medical Center, Boston, Massachusetts 02111.

There are currently no accepted criteria for positive Western blots in
Lyme
disease. In a retrospective analysis of 225 case and control subjects,
the best
discriminatory ability of test criteria was obtained by requiring at
least 2 of
the 8 most common IgM bands in early disease (18, 21, 28, 37, 41, 45,
58, and 93
kDa) and by requiring at least 5 of the 10 most frequent IgG bands
after the
first weeks of infection (18, 21, 28, 30, 39, 41, 45, 58, 66, and 93
kDa). When
these definitions were tested in a prospective study of all 237
patients seen in
a diagnostic Lyme disease clinic during a 1-year period and in 74
patients with
erythema migrans or summer flu-like illnesses, the IgM blot in early
disease had
a sensitivity of 32% and a specificity of 100%; the IgG blot after the
first
weeks of infection had a sensitivity of 83% and a specificity of 95%.
Among
patients with indeterminate IgG responses by ELISA, 6 of 9 patients
with active
Lyme disease had positive blots compared with 2 of 34 patients with
other
illnesses (P < .001). Thus, Western blotting can be used to increase
the
specificity of serologic testing in Lyme disease.
PMID: 8380611 [PubMed - indexed for MEDLINE]

(1993)  "Antibody Responses to Three Genomic Groups.."
Dressler/Steere
1: J Infect Dis. 1994 Feb;169(2):313-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

Antibody responses to the three genomic groups of Borrelia burgdorferi
in
European Lyme borreliosis.

Dressler F, Ackermann R, Steere AC.

Division of Rheumatology/Immunology, New England Medical Center, Tufts
University School of Medicine, Boston, Massachusetts 02111.

The antibody responses to the three genomic groups of Borrelia
burgdorferi (B.
burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii) were

determined in 97 German patients with various manifestations of Lyme
borreliosis. The geometric mean antibody titers in each patient group,
determined by ELISA, were similar with each antigen preparation. By
Western
blotting, however, patients with meningopolyneuritis tended to respond
to more
spirochetal polypeptides of B. garinii, the group 2 strain, whereas
those with
arthritis recognized more antigens of B. afzelii, the group 3 strain (P

< .03),
as did those with acrodermatitis. Only 1 patient each with erythema
migrans,
arthritis, or acrodermatitis had weak reactivity with outer surface
protein A
(OspA), and none responded to OspB. It is concluded that differences
among the
three groups of B. burgdorferi may result in variations in the antibody

response
in European Lyme borreliosis.  PMID: 8106763 [PubMed - indexed for
MEDLINE]

G39/40 is high-passage (no good)

Steere demonstrates that there is a different antibody profile in
neurologic Lyme patients,
than there is for Lyme arthritis

       Sequence described by Steere, kilodaltons (kD)

EARLY, with erythema migrans
41

       1-5 months after disease onset
                       83
                       66

                               27
                               15
                                       months to years
                                       75
                                       60
                                       34 (Osp B)
                                       31 (Osp A)
                                       29
                                       17

Page 936:  34, 31, 29, and 17 were "bound strongly," which means
there was a high antibody concentration.  This was not the case later,
in Dressler/Steere, and OspA and B were left out of the serodiagnostic
standard  (this is "bogus" science).
                       (See other notations in that text.)

The 1994  CDC Dearborn Conference criteria are supposed to be for
"early Lyme," but clearly "5 months to years," is not "early
Lyme," and no one agreed with Steere, except MarDx, who had been
given CDC Dearborn-positive arthritis blood to qualify their test kits,

and who also have been given the contracts for both vaccine trials.
http://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm

The ImmuLyme trial began in March 1994, before Dearborn even convened,
and 6 years later, the principal investigator, Leonard Sigal reported
that he could not even read his Western Blots, in people who were
vaccinated.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

1: N Engl J Med. 1998 Jul 23;339(4):216-22.
Erratum in:
   N Engl J Med 1998 Aug 20;339(8):571.

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface
protein A
to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme
Disease
Vaccine Study Consortium.

Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R,
Hilton E,
Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL,
Sabetta JR,
Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE.

Department of Medicine, University of Medicine and Dentistry of New
Jersey-Robert Wood Johnson Medical School, New Brunswick 08903-0019,
USA.

BACKGROUND: Lyme disease is a multisystem inflammatory disease caused
by
infection with the tick-borne spirochete Borrelia burgdorferi and is
the most
common vector-borne infection in the United States. We assessed the
efficacy of
a recombinant vaccine consisting of outer-surface protein A (OspA)
without
adjuvant in subjects at risk for Lyme disease. METHODS: For this
double-blind
trial, 10,305 subjects 18 years of age or older were recruited at 14
sites in
areas of the United States where Lyme disease was endemic; the subjects

were
randomly assigned to receive either placebo (5149 subjects) or 30
microg of OspA
vaccine (5156 subjects). The first two injections were administered 1
month
apart, and 7515 subjects also received a booster dose at 12 months. The

subjects
were observed for two seasons during which the risk of transmission of
Lyme
disease was high. The primary end point was the number of new
clinically and
serologically confirmed cases of Lyme disease. RESULTS: The efficacy of

the
vaccine was 68 percent in the first year of the study in the entire
population
and 92 percent in the second year among the 3745 subjects who received
the third
injection. The vaccine was well tolerated. There was a higher incidence

of mild,
self-limited local and systemic reactions in the vaccine group, but
only during
the seven days after vaccination. There was no significant increase in
the
frequency of arthritis or neurologic events in vaccine recipients.
CONCLUSIONS:
In this study, OspA vaccine was safe and effective in the prevention of

Lyme
disease. PMID: 9673299 [PubMed - indexed for MEDLINE]

(1993)  March,    Wormser and Nowakowski:   Use Western blots for ELISA

negatives,  Dressler/Steere proposal only 13-25% accurate.  (The
standard adopted by the CDC is the opposite- It says not to do a
Western Blot on ELISA negatives.)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

1: J Clin Microbiol. 1993 Dec;31(12):3090-5.

Erratum in:
   J Clin Microbiol 1994 Mar;32(3):860.

Serodiagnosis in early Lyme disease.

Aguero-Rosenfeld ME, Nowakowski J, McKenna DF, Carbonaro CA, Wormser
GP.

Department of Pathology, New York Medical College, Valhalla.

Using a commercially available enzyme-linked immunosorbent assay
(ELISA) and an
immunoblot assay (IB), we tested sera from 100 patients with erythema
migrans
(EM) seen in 1991 a the Westchester County Medical Center Lyme Disease
Diagnostic Center. Convalescent-phase sera were available from 59
patients.
Fifty-five patients had EM of < 7 days' duration, 31 had EM of 7 to 14
days'
duration, and 14 had EM of > 14 days' duration. During the acute phase
of
infection, 35 patients had a positive ELISA result and 43 had a
positive IB
result by the recently published criteria of Dressler et al. (F.
Dressler, J. A.
Whalen, B. N. Reinhardt, and A. C. Steere, J. Infect. Dis. 167:392-400,

1993)
for interpretation of IB in patients with Lyme disease. A greater
sensitivity of
IB was observed in patients with EM of < 7 days' duration, as follows:
14 of 55
(25%) for IB versus 7 of 55 (13%) for ELISA (P = 0.144). Sera of all 14

patients
with EM of > 14 days' duration were reactive by both tests, as follows:

13
positive and 1 equivocal by ELISA and 12 positive and 2 indeterminate
by the IB.
The band reactivity most frequently observed in the IB was to the 41-
and 25-kDa
antigens, the latter being the most frequent band observed in
immunoglobulin M
blots. Seroconversion was observed in 74 and 64% of evaluable patients
by ELISA
and IB, respectively, despite the use of antibiotic therapy.
PMID: 8308100 [PubMed - indexed for MEDLINE]

(1993)  "Overdiagnosis" article, Steere    Patients not positive
"in our labs" - using bogus strains  (high-passage G39/40, and
FRG- a German strain)

       Most people will not have antibodies to these weakened or
useless
strains.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

1: JAMA. 1993 Apr 14;269(14):1812-6.

The overdiagnosis of Lyme disease.

Steere AC, Taylor E, McHugh GL, Logigian EL.

Division of Rheumatology/Immunology, New England Medical Center,
Boston, MA
02111.

OBJECTIVE--To analyze the diagnoses, serological test results, and
treatment
results of the patients evaluated in a Lyme disease clinic, both prior
to
referral and from current evaluation. DESIGN--Retrospective case survey

of
prescreened patients. SETTING--Research and diagnostic Lyme disease
clinic in a
university hospital. PATIENTS--All 788 patients referred to the clinic
during a
4.5-year period who were thought by the referring physician or the
patient to
have a diagnosis of Lyme disease.
MAIN OUTCOME MEASUREMENTS--Symptoms and signs
of disease, immunodiagnostic tests of Lyme disease, and tests of
neurological
function. RESULTS--Of the 788 patients, 180 (23%) had active Lyme
disease,
usually arthritis, encephalopathy, or polyneuropathy. One hundred
fifty-six
patients (20%) had previous Lyme disease and another current illness,
most
commonly chronic fatigue syndrome or fibromyalgia; and in 49 patients,
these
symptoms began soon after objective manifestations of Lyme disease. The

remaining 452 patients (57%) did not have Lyme disease. The majority of

these
patients also had the chronic fatigue syndrome or fibromyalgia; the
others
usually had rheumatic or neurological diseases. Of the patients who did

not have
Lyme disease, 45% had had positive serological test results for Lyme
disease in
other laboratories, but all were seronegative in our laboratory. Prior
to
referral, 409 of the 788 patients had been treated with antibiotic
therapy. In
322 (79%) of these patients, the reason for lack of response was
incorrect
diagnosis. CONCLUSIONS--Only a minority of the patients referred to the

clinic
met diagnostic criteria for Lyme disease. The most common reason for
lack of
response to antibiotic therapy was misdiagnosis.
PMID: 8459513 [PubMed - indexed for MEDLINE]

(1993, Dec)  US PATENT- Fikrig (Yale) 5618533  Bb Flagellin (94%
accurate, early, and specific test)

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=P...

United States Patent    5,618,533
Flavell ,   et al.      April 8, 1997

Flagellin-based polypeptides for the diagnosis of lyme disease
Abstract
Diagnostic means and methods for Lyme disease comprising B. burgdorferi

flagellin polypeptides and antibodies. Compositions and methods
comprising neuroborreliosis-associated antigens useful for the
detection, treatment and prevention of neuroborreliosis, arthritis,
carditis and other manifestations of Lyme disease.
Inventors: Flavell; Richard A. (Killingworth, CT); Fikrig; Erol
(Guilford, CT); Berland; Robert (Kingston, NY) Assignee: Yale
University (New Haven, CT) Appl. No.: 166160 Filed: December 10, 1993

1994, March through 1999, August- the ImmuLyme trial- A MUST READ

1994 June-  FDA Meeting,   Ray Dattwyler recommends using serial
Western Blots to assesss vaccines.

(1994, Oct 7)  US PATENT- 5747294   Yale's OspA patent

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=P...

United States Patent    5,747,294
Flavell ,   et al.      May 5, 1998

Compositions and methods for the prevention and diagnosis of lyme
disease
Abstract
Methods and compositions for the prevention and diagnosis of Lyme
disease. OspA and OspB polypeptides and serotypic variants thereof,
which elicit in a treated animal the formation of an immune response
which is effective to treat or protect against Lyme disease as caused
by infection with B. burgdorferi. Anti-OspA and anti-OspB antibodies
that are effective to treat or protect against Lyme disease as caused
by infection with B. burgdorferi. A screening method for the selection
of those OspA and OspB polypeptides and anti-OspA and anti-OspB
antibodies that are useful for the prevention and detection of Lyme
disease. Diagnostic kits including OspA and OspB polypeptides or
antibodies directed against such polypeptides.

Inventors:      Flavell; Richard A. (Killingworth, CT); Kantor; Fred S.

(Orange, CT); Barthold; Stephen W. (Madison, CT); Fikrig; Erol
(Guilford, CT)
Assignee:       Yale University (New Haven, CT)
Appl. No.:      320161
Filed:  October 7, 1994

"Early in human infection, antibodies are generated primarily against
a 41 kD flagella-associated antigen. Later on, high titers appear to
both OspA and OspB..."

(1994, Oct)  Dearborn, MI CDC Conference data:  Recommendations:  DO
NOT USE HIGH PASSAGE STRAINS

       Lists interest-conflicted parties

See my Jan 2001 FDA testimony (How to pass off a bogus vaccine:  Make
its failure undetectable):

http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2_11.pdf

(1996, March)   US PATENT- 6045804  Persing (Corixa)  OspA-less
spirochete

United States Patent    6,045,804
Persing         April 4, 2000

Method for detecting B. burgdorferi infection
Abstract
The present invention provides a method for detecting B. burgdorferi
infection utilizing an antigen preparation lacking a detectable level
of outer surface protein A (OspA). The antigen preparation is made from

an isolate of B. burgdorferi that lacks the plasmid encoding outer
surface protein A (OspA). The method of the invention discriminates B.
burgdorferi infection from OspA vaccination.

Inventors:      Persing; David H. (Rochester, MN)
Assignee:       Mayo Foundation for Medical Educational Research
(Rochester,
MN)
Appl. No.:      612231
Filed:  March 7, 1996

       -Mentions problems with Immunoblotting

- Mentions there is a need for a test to detect Lyme in vaccinated and
non-vaccinated patients-  WHICH IS THE ENTIRE NATURE OF THIS SCAM.

-Evidence of "partnership" between SmithKline, Corixa and Imugen
(also L2 Diagnostics, the Yale Lyme and Lupus clinic biotech spinoff.
This spinoff firm was funded by the Yale Endowment fund.

2000,  "Detection of Multiple Reactive Species..."  (Imugen's
Phillip Molloy,
Victor Berardi, and Leonard Sigal, with Dave Persing.).

http://www.journals.uchicago.edu/CID/journal/issues/v31n1/991200/9912...

Why weren't these unreadable blots reported to the FDA, and how could
Sigal have reported a 92% safe and effective vaccine with unreadable
blots?

Or is this just a promotion for use of their patented test, for which
only Imugen and L2 Diagnostics are licensed from Corixa to use?
http://www.yale.edu/opa/newsr/98-12-22-01.all.html

Yale, SmkithKline, Corixa, Imugen-THE PARTNERSHIP:

http://www.imugen.com/news_release1.htm

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=149722&tool...

Please see my notes in that report

Henry Feder (UCONN) ran a vaccine trial on European children, when
there is practically none of that kind of OspA in Europe, according to
Steere.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&...

1: J Pediatr. 1999 Nov;135(5):575-9.

Comment in:
   J Pediatr. 1999 Nov;135(5):539-41.
   J Pediatr. 2001 Apr;138(4):609-10.

Immunogenicity of a recombinant Borrelia burgdorferi outer surface
protein A
vaccine against Lyme disease in children.

Feder HM Jr, Beran J, Van Hoecke C, Abraham B, De Clercq N, Buscarino
C, Parenti
DL.

Department of Family Medicine, University of Connecticut Health Center,

Farmington, Connecticut 06030-1406, USA.

BACKGROUND AND OBJECTIVE: A recombinant lipoprotein vaccine against
Lyme
disease, containing 30 microg of Borrelia burgdorferi outer surface
protein A
(OspA) with aluminum adjuvant, has been shown in a large US field trial

of
subjects >/=15 years of age to offer 76% efficacy against clinical Lyme

disease
after 3 injections given at 0, 1, and 12 months. Lyme disease is also
an
important problem in children; thus, OspA vaccine trials in children
are needed.
The purpose of this study was to investigate the safety and
immunogenicity of 2
different doses of lipoprotein OspA with aluminum adjuvant vaccine in
healthy
children 5 to 15 years of age in a double-blind, randomized study.
STUDY DESIGN:
In a double-blind study, 250 children from the Czech Republic were
randomly
assigned to receive 15 microg or 30 microg of OspA vaccine at 0, 1, and

2
months. Serum samples, obtained before vaccination and 1 month after
the second
and third doses, were analyzed for antiOspA antibody. Solicited and
unsolicited
symptoms were collected from diary cards. RESULTS: Local pain at the
injection
site was reported by approximately 76% of the 250 children. Headaches
(after 5%
to 18% of the injections) and malaise (after 2% to 16% of the
injections) were
the most frequently reported general symptoms. Local and generalized
symptoms
were not different between the 15 microg and 30 microg groups, and all
symptoms
resolved within 4 days. Both doses were highly immunogenic, with the 30

microg
dose eliciting higher antibody levels. Seroconversion occurred in 99%
of the 250
children. CONCLUSIONS: The OspA vaccine against Lyme disease was well
tolerated
and highly immunogenic in children.
PMID: 10547245 [PubMed - indexed for MEDLINE]

2005, Feb-  CDC releases more of their nonsense about what is a valid
test, and imply that we need "use of validated laboratory tests,"
but CDC's are hardly valid, FDA's own criteria.

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5405a6.htm

2005, May,  Reponse to Dr. Raphael Stricker in which he states: "To
my knowledge, the CDC website does not state that the serological
criteria recommended by the CDC are not appropriate for use in clinical

diagnosis."

"Clinical" means signs and symptoms, independent of lab work.

It is on the Department of Health and Human Services' website, in
which CDC states that there is no substitute for sound clinical
judgment:   PAUL MEAD:  "For this reason, CDC has repeatedly stated
that the surveillance case definition is not a substitute for sound
clinical judgment."
http://www.hhs.gov/asl/testify/t040129.html

------------------------------------------------------------------------------------------------------------------------------
kathLOON's post where she admits to no accomplishments with her
"cartoon group of activists":

http://groups.google.com/group/sci.med.diseases.lyme/msg/5200997fa77e7609?dmode=
source&hl=en

kathleen
Apr 28, 5:57 pm   hide options

Newsgroups: sci.med.diseases.lyme, alt.flame.psychiatry,
alt.support.autism, alt.support.child-protective-services
From: "kathleen" <kathleen.dick...@snet.net> - Find messages by this
author
Date: 28 Apr 2005 15:57:54 -0700
Local: Thurs, Apr 28 2005 5:57 pm
Subject: Good Idea...Re: Weisnut - for attn of Cal-Lyme
Reply to Author | Forward | Print | Individual Message | Show original

Agree.

What do you want to do, then?

Want to organize an international
letter-writing campaign complaining
of You Know Which agency in Atlanta?

Copy the WHO?

I could put a template on my website
for people to copy down.  Or, we could
make it something that the Lyme webrings
all share.

If there are 800,000 people in this country
alone who have CFIDS (according to the CDC,
so that means more like 8 million), imagine
how many there are in Europe and Australia?

We could do a lot.  Contrary to popular
belief, I still have some connections.

What happened in the past, when we tried
to form an international patient advocacy
group, was, we formed one, then all the groups
broke off, and formed their own little
autocracies, headed by local pinheads.

I ran ActionLyme in a democratic way, only
we yeilded little actual action.  I maintain
hope, as does Lisa, and probably everyone
else, that eventually we will get pissed
enough to do something global- PACIFIST-
Global.

You know, targetted not at each other,
for a change. (Just nevermind Weisman, he
is hopeless.)

Usually elected officials in this country
respond to a mass letter writing campaign.
That's how we got New York going... although
it never went anywhere, because of the splinter
groups and pinheaded local activist autocracies.

This news from CDC is good, except I am a
little leary about them now screening people
of color- that chronically rejected group-
that group who get pared the cheap end of
the stick in every arena... for "Chronic Illness"
in Georgia, because I am afraid the outcome will
be the usual-  "These people are not sick, they
are just depressed."  Or, "Their problem is poverty
and not illness."

To which, The Heritage Foundation will respond:
"Quit whining, your problems are your own
stupid fault (Sally Satel)."
http://www.sallysatelmd.com/

CDC says they want to take blood this time,
from CFIDS people, which is a switch from psychiatric
surveys as the usual means to determine CFIDS is not
real.

Whattya think?

The issue is funding, but we, in the US, funded
huge studies to determine Autism is not due to the
Thimerosal, when CDC knew it wasn't- It's due
to the MMR antigens themselves (revealed by
the fact that CDC has now declared Rubella
finally gone- "Just nevermind those pesky break-
through strains, and the post-vaccinal encephalitis
resulting in the phenomenal increase in "Autism"...).

And we funded huge studies to say we are too
fat, and therefore unhealthy, only for that to be
retracted by CDC.

Everyone should study the CDC's website, if
they want to know what they intend for us.

Next its cop-enforced quarantines- But the prisons
are already overflowing with tuberculosis and
AIDS.  What do they have in mind?  First prison,
then Leper Colonies?

We should all write Small Business Innovation
grant proposals for cash to build such leper
colonies and related prisons for people will
illnesses.  I don't see anyone starting a
"National string of psychiatric hospitals for
adult victims of MMR brain damage."

That should be a healthy market.

I've tried organizing.  Rallying Lyme
patients to collective action is harder
than herding cats.  The CFIDS/ME patients
are our twins.  And they refuse to join
us even in simply taking on the CDC.  We
told them they could HAVE their non-diagnosis
if they love so much being abused, just
join us in an action to call on the CDC
to be accountable.  I got the same result
with the Autistic parents group...

All the little nitwit e-list managers so much
want to be boss, that nothing gets done.

People fail to see what the result is
of not having paid lobbyists.  Said more
clearly: People fail to realize that we have
to rely on each other if we are not rich.

Said another way: How about we start
a Democracy and have a Constitution.  The
First Amendment could be Free Speech.

Ya think?

Kathleen